<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1887-8571</journal-id>
<journal-title><![CDATA[Sanidad Militar]]></journal-title>
<abbrev-journal-title><![CDATA[Sanid. Mil.]]></abbrev-journal-title>
<issn>1887-8571</issn>
<publisher>
<publisher-name><![CDATA[Ministerio de Defensa]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1887-85712019000100014</article-id>
<article-id pub-id-type="doi">10.4321/s1887-85712019000100003</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Detección e identificación de cannabinoides sintéticos en muestras sólidas y biológicas]]></article-title>
<article-title xml:lang="en"><![CDATA[Detection and Identification of Synthetic Cannabinoids in Solid and Biological Samples]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Martínez-Galdámez]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Llorente Ballesteros]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Urquía Grande]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[López Colón]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto de Toxicología de la Defensa  ]]></institution>
<addr-line><![CDATA[Madrid ]]></addr-line>
<country>España</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Instituto de Toxicología de la Defensa  ]]></institution>
<addr-line><![CDATA[Madrid ]]></addr-line>
<country>España</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Instituto de Toxicología de la Defensa  ]]></institution>
<addr-line><![CDATA[Madrid ]]></addr-line>
<country>España</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Instituto de Toxicología de la Defensa  ]]></institution>
<addr-line><![CDATA[Madrid ]]></addr-line>
<country>España</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>03</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>03</month>
<year>2019</year>
</pub-date>
<volume>75</volume>
<numero>1</numero>
<fpage>14</fpage>
<lpage>18</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S1887-85712019000100014&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S1887-85712019000100014&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S1887-85712019000100014&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción: Los cannabinoides sintéticos (CBS) son sustancias que imitan los efectos del delta-9-tetrahidrocannabinol (THC). Los CBS no dan positivo en los tests de cribado de drogas habituales, dado que no son detectables por las técnicas de identificación. La cromatografía de gases con espectrometría de masas (GC-MS) es la técnica de referencia para el análisis de los CBS. Presentamos un método de detección y cuantificación de metabolitos de CBS en orina mediante cromatografía líquida acoplada a espectrometría de masas de alta resolución (HPLC-HRMS).  Objetivos: Identificación de CBS en muestras solidas mediante GC-MS y optimización e implementación de un método para la detección de CBS en orina por HPLC-HRMS.  Material y métodos: Análisis de 8 muestras sólidas de compuestos herbales y de 30 muestras de orina de consumidores sospechosos de CBS remitidas al ITOXDEF para su identificación y confirmación.  Resultados: Se han identificado 8 CBS en los 8 compuestos herbales mediante GC-MS y dos CBS (UR-144 y JWH-018) en las muestras de orina.  Conclusiones: En el Instituto de Toxicología de Defensa se ha puesto en marcha un método analítico para la detección de cannabinoides sintéticos en orina, empleando como técnica analítica instrumental un equipo de cromatografía líquida de alta resolución (HPLC) acoplada a espectrometría de masas de alta resolución (HRMS). Se considera que el método analítico ha sido desarrollado satisfactoriamente, dado que los datos obtenidos en los estudios realizados demuestran que el método es apto para su uso previsto. En el futuro se podrán analizar también los CBS en líquidos biológicos como son pelo y saliva, con las ventajas siguientes: disminuye tiempo de análisis, es más sensible y más exacto, y es menos invasivo.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[SUMMARY  Introduction: Synthetic cannabinoids (SC) are substances that mimic the effects of delta-9-tetrahydrocannabinol (THC). SCs do not cause a positive drug test for marijuana or other illegal drugs, since they are not detectable in standard drug tests. Gas chromatography-mass spectrometry (GC-MS) is one of the most commonly used techniques for analysis of synthetic cannabinoids. We present a method for the detection and quantitation of several urinary synthetic cannabinoids metabolites by high-performance liquid chromatography coupled with high resolution mass spectrometry (HPLC-HRMS).  Objectives: Identification of SC in suspicious solid samples by GC.MS, and optimization and implementation of an analytical method for the detection of SC in urine, using HPLC tandem with HRMS.  Material and methods: Analysis of solid samples: A total of eight samples received were analyzed for identification and confirmation. Urine analysis: We analyzed a total of 30 urine samples with possible suspicion of having used synthetic cannabis.  Results: In the present project, synthetic cannabinoids were identified 8 in 8 herbal incense products by employing GC-MS and 2 were determined in 30 urine samples by HPLC.  Conclusions: Like all other drugs of abuse, the confirmation analysis is based on GC-MS. We have optimized and implemented an analytical method for the detection of SCs in urine, using a HPLC tandem with HRMS as an analytical technique. The analytical method is believed to have been satisfactorily developed which is proved by the data gathered from the studies carried out proving thus its adequacy to the previewed use. Further research might include the analysis of the CBS in biological liquids (hair, saliva) which presents added advantages such as the reduction of the procedure time, its less invasive character and greater precision.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Cannabinoides sintéticos]]></kwd>
<kwd lng="es"><![CDATA[Spice]]></kwd>
<kwd lng="en"><![CDATA[Synthetic cannabinoids]]></kwd>
<kwd lng="en"><![CDATA[Spice]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="">
<collab>United Nations Office on Drugs and Crime (UNODC)</collab>
<source><![CDATA[Synthetic cannabinoids in herbal products]]></source>
<year>2011</year>
<publisher-loc><![CDATA[Vienna ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tracy]]></surname>
<given-names><![CDATA[DK]]></given-names>
</name>
<name>
<surname><![CDATA[Wood]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Baumeister]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Novel psychoactive substances: identifying and managing acute and chronic harmful use]]></article-title>
<source><![CDATA[BMJ]]></source>
<year>2017</year>
<volume>356</volume>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="">
<collab>United Nations Office on Drugs and Crime (UNODC)</collab>
<source><![CDATA[World Drug Report 2017. Market analysis of synthetic drugs Amphetamine-type stimulants, new psychoactive substances]]></source>
<year>2017</year>
<publisher-loc><![CDATA[Vienna ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<collab>European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)</collab>
<article-title xml:lang=""><![CDATA[Report on the risk assessment of methyl 2-[[1-(cyclohexylmethyl)-1H-indole-3-carbonyl]amino]-3,3-dimethylbutanoate (MDMB-CHMICA) in the framework of the Council Decision on new psychoactive substances]]></article-title>
<source><![CDATA[Risk Assessments]]></source>
<year>2014</year>
<numero>19</numero>
<issue>19</issue>
<publisher-loc><![CDATA[Luxenburg ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="">
<source><![CDATA[BOE]]></source>
<year>2016</year>
<numero>120</numero>
<issue>120</issue>
<page-range>32819</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="">
<source><![CDATA[BOE]]></source>
<year>2018</year>
<numero>175</numero>
<issue>175</issue>
<page-range>73005</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="">
<collab>Observatorio europeo de las drogas y toxicomanías</collab>
<source><![CDATA[Informe Europeo sobre drogas. Tendencias y Novedades]]></source>
<year>2018</year>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="">
<collab>Observatorio español de las Drogas y las Adicciones (OEDA)</collab>
<collab>Delegación del Gobierno para el Plan Nacional sobre Drogas (DGPNSD)</collab>
<source><![CDATA[Informe 2017. Alcohol, tabaco y drogas ilegales en España]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="">
<collab>Ministerio de Sanidad, Servicios Sociales e Igualdad. Secretaría de Estado de Servicios Sociales e Igualdad. Delegación del Gobierno para el Plan Nacional sobre Drogas</collab>
<source><![CDATA[Estrategia Nacional sobre Adicciones 2017-2026]]></source>
<year>2018</year>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="">
<collab>Ministerio de Defensa. Dirección General de Personal. División del Servicio de Apoyo al Personal</collab>
<source><![CDATA[II Plan General de Prevención de Drogas en las Fuerzas Armadas]]></source>
<year>2010</year>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tait]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Caldicott]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Mountain]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Hill]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
<name>
<surname><![CDATA[Lenton]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment]]></article-title>
<source><![CDATA[Clin Toxicol (Phika)]]></source>
<year>2016</year>
<volume>54</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-13</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="">
<collab>European Monitoring Centre for Drugs and Drug Addiction</collab>
<source><![CDATA[EMCDDA-Europol Joint Report on a new psychoactive substance: methyl 2-[[1-(cyclohexylmethyl)indole-3-carbonyl]amino]-3,3-dimethylbutanoate (MDMB-CHMICA)]]></source>
<year>2016</year>
</nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hermanns-Clausen]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kithinji]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Spehl]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Angerer]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Franz]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Eyer]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Auwärter]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adverse effects after the use of JWH-210 - a case series from the EU Spice II plus project]]></article-title>
<source><![CDATA[Drug Test Anal]]></source>
<year>2016</year>
<volume>8</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1030-8</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="confpro">
<collab>World Health Organization (WHO)</collab>
<source><![CDATA[UR-144: Critical-Review Report. Agenda item 4.8]]></source>
<year></year>
<conf-name><![CDATA[ Expert Committee on Drug Dependence, Thirty-sixth]]></conf-name>
<conf-date>16-20 June 2014</conf-date>
<conf-loc>Geneva </conf-loc>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Adamowicz]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Gieron]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Gil]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Lechowicz]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Skulska]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Tokarczyk]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The effects of synthetic cannabinoid UR-144 on the human body-A review of 39 cases]]></article-title>
<source><![CDATA[Forensic Sci Int]]></source>
<year>2017</year>
<volume>273</volume>
<page-range>18-21</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="confpro">
<collab>World Health Organization (WHO)</collab>
<source><![CDATA[JWH-018; Critical Review Report. Agenda item 4.5]]></source>
<year></year>
<conf-name><![CDATA[ Expert Committee on Drug Dependence, Thirty-sixth]]></conf-name>
<conf-date>16-20 June 2014</conf-date>
<conf-loc>Geneva </conf-loc>
</nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="book">
<collab>United Nations Office on Drugs and Crime (UNODC)</collab>
<source><![CDATA[Recommended methods for the Identification and Analysis of Synthetic Cannabinoid Receptor Agonists in Seized Materials. Manual for use by National Drug Analysis Laboratories]]></source>
<year>2013</year>
<publisher-loc><![CDATA[New York ]]></publisher-loc>
<publisher-name><![CDATA[United Nations]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alvarez Heredia]]></surname>
<given-names><![CDATA[Karol F]]></given-names>
</name>
</person-group>
<source><![CDATA[Chemical Identification of Synthetic Cannabinoids in Herbal Incense Products]]></source>
<year>2017</year>
<publisher-name><![CDATA[CUNY Academic Works]]></publisher-name>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
